Last reviewed · How we verify

NCT03543228: Prefect

MyoStrain CMR for the Detection of Cardiotoxicity

Completed Last updated 25 June 2021
What this trial tests

trial testing MyoStrain in Cardiotoxicity in 63 participants. Completed in 31 January 2020.

Timeline
1 August 2017
Primary endpoint
31 January 2020
31 January 2020

Quick facts

Lead sponsorMyocardial Solutions
StatusCompleted
Study typeOBSERVATIONAL
Enrollment63
Start date1 August 2017
Primary completion31 January 2020
Estimated completion31 January 2020
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Myocardial Solutions

Who can join

Adults 18 to 80, any sex, with Cardiotoxicity or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Prefect Pilot Study evaluates the use of the EC approved MyoStrain SENC CMR Imaging System to detect cardiotoxicity from drugs used to treat cancer (e.g. Breast Cancer and Lymphomas).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up.
    Giusca S, Korosoglou G, Montenbruck M, Geršak B, et al · · 2021 · cited 55× · PMID 34126756 · DOI 10.1161/circimaging.121.012459
  2. Abstracts of the Heart Failure 2019 and the World Congress on Acute Heart Failure, 25-28 May 2019, Megaron Athens International Conference Centre, Greece.
    · 2019 · cited 5× · PMID 32745277 · DOI 10.1002/ejhf.1488
  3. Relationship Between Quality of Life Indicators and Cardiac Status Indicators in Chemotherapy Patients.
    Geršak BM, Kukec A, Steen H, Montenbruck M, et al · · 2021 · cited 3× · PMID 34917188 · DOI 10.2478/sjph-2021-0028
  4. Cardiotoxicity Monitoring in Patients With Cancer: Focus on Safety and Clinical Relevance.
    Suero-Abreu GA, Ganatra S, Neilan TG. · · 2021 · cited 2× · PMID 33793304 · DOI 10.1200/op.21.00075
  5. Myocardial Strain Measurements Obtained with Fast-Strain-Encoded Cardiac Magnetic Resonance for the Risk Prediction and Early Detection of Chemotherapy-Related Cardiotoxicity Compared to Left Ventricular Ejection Fraction.
    Lenihan D, Whayne J, Osman F, Rivero R, et al · · 2025 · PMID 40804912 · DOI 10.3390/diagnostics15151948

Verify or expand the search:

Other trials of MyoStrain

Trials testing the same drug.

Other recruiting trials for Cardiotoxicity

Currently open trials in the same condition.

Other Myocardial Solutions trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03543228.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing